High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab
Crossref DOI link: https://doi.org/10.1007/s12094-016-1596-8
Published Online: 2016-12-22
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kumar, S. S.
Tomita, Y.
Wrin, J.
Bruhn, M.
Swalling, A.
Mohammed, M.
Price, T. J.
Hardingham, J. E. http://orcid.org/0000-0001-8277-1199
Funding for this research was provided by:
Cancer Council South Australia (1028595)
License valid from 2016-12-22